160 million earnings from SANLI medical first half year, extend field to medical service

At the end of August, SANLI Medical issued its semi-annual report for 2018. The report shows that in the first half of 2018, the company achieved a revenue of 160 million yuan. The company’s main business, such as vacuum blood collection system, continued to maintain a steady growth in revenue, accelerated the promotion of new products such as liquid biopsy tube analysis and hospital intelligent blood collection management system. SANLI Medical is striving to bring new products to the company for new performing profit.

Competitiveness Promotion of traditional business

At present, SANLImedical products and services have covered more than 100 countries and regions around the world, providing products and technical services for nearly 10,000 medical institutions. During the reporting period, the domestic market share of the company’s vacuum blood collection system grew steadily, and the combined contribution rate of vacuum blood collection products to the company’s profits in the first half of 2018 reached 78.26%.

The company has been engaged in mutation control research before specimen analysis for more than 20 years, and is the first enterprise in vacuum blood collection system industry in China. At present, the business company has six-core proprietary technologies, more than 60 scientific research patents, and the company’s main product vacuum blood collection system provides a strong technical support.

As a leader in the vacuum blood vessel industry, the company always adheres to the “Science and technology first” and “Innovation first” higher than the “commercial criteria” and emphasizes the vacuum blood vessel products should have good sterile technology. The company has always stood at the higher standards to define the blood vessel collection business, with the rapid implementation of industry standards, so that products can return to technical requirements and early screening value. Therefore, vacuum blood collection in the industry is no longer simply a tool for blood collection or medical order needs, but return to the sample analysis before mutation control tool, which will further raise the industry technical threshold, greatly enhance the concentration of the industry. With the increase of industry threshold and the stricter enforcement of industry regulations, the market competition pattern will tend to be in order, and the vacuum blood collection system, the main product of SANLI medical treatment, is expected to further release its economic benefits.

During the reporting period, the experts of SANLI Medical Products participated in the revision of the Recommended Health Industry Guidelines issued by the National Health Commission. In April 2018, the National Health Council issued the Recommended Health Industry Guidelines for the Performance Verification of Vacuum Vascular Collection, which will be implemented in November 2018.

Extension of medical industry to medical service

SANLI Medical is studying intelligent blood collection management system, medical service system, cloud computing analysis data, to further promote the high-tech and humanized medical services.